We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    talimogene laherparepvec, 002/03
Previous Study | Return to List | Next Study

An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02574260
Recruitment Status : Completed
First Posted : October 12, 2015
Results First Posted : December 17, 2015
Last Update Posted : December 17, 2015
Information provided by (Responsible Party):
BioVex Limited

Brief Summary:
The primary objective of this extension study was to further assess the safety and tolerability of talimogene laherparepvec. Secondary objectives were to assess objective tumor response rate and survival.

Condition or disease Intervention/treatment Phase
Melanoma Biological: Talimogene Laherparepvec Phase 2

Detailed Description:

This was an extension study to the multicenter, open-label, phase 2 Study 002/03 (NCT00289016). Participants who had received the maximum 24 treatments under Study 002/03 and met the inclusion and exclusion criteria were eligible to enroll.

Participants continued to receive talimogene laherparepvec until discontinuation criteria were met. The discontinuation criteria were complete response, clinically significant progressive disease that rendered further dosing futile, receipt of 24 treatments or 12 months on treatment (whichever was longer), occurrence of an unacceptable toxicity, death, investigator determination that other treatment was warranted, or another criterion for withdrawal from treatment (participant request, noncompliance with study procedures, or sponsor request).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Extension Protocol for Extended Use of OncoVEX^GM-CSF for Eligible Patients Participating in Study 002/03: Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Study Start Date : August 2008
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Talimogene Laherparepvec
Participants received talimogene laherparepvec 10⁸ plaque forming units (PFU)/mL (up to 4 mL depending on tumor size) administered intratumorally every 2 weeks, on Day 1 and Day 15 of 28-day cycles until discontinuation criteria were met.
Biological: Talimogene Laherparepvec
Administered by intratumoral injection.
Other Names:
  • OncoVEX^GM-CSF
  • T-VEC

Primary Outcome Measures :
  1. Number of Participants With Adverse Events [ Time Frame: From the first dose of talimogene laherparepvec in Study 002-03-E and within 30 days of the last dose; median duration of treatment was 267 days. ]

    The severity of an adverse event (AE) was graded according to Common Toxicity Criteria for Adverse Events (CTCAE) Version 3 (1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death).

    Serious adverse events include death, life-threatening events, events requiring or prolonging hospitalization, result in persistent or significant disability/incapacity, or a congenital anomaly/birth defect, or otherwise important medical events that may jeopardise the patient or require intervention to prevent one of the above outcomes.

Secondary Outcome Measures :
  1. Number of Participants With an Objective Response [ Time Frame: Every 12 weeks from the start of therapy in this extension protocol, or 12 weeks from the last assessment in the 002/03 protocol (whichever date is later) through 30 days after administration of the last dose; median duration of treatment was 267 days. ]

    Objective response is defined as participants with an overall best response of complete response or partial response. The objective response to treatment was assessed by computed tomography (CT) scanning or other clinical measurement using modified Response Evaluation Criteria In Solid Tumors (RECIST).

    Responses must have been confirmed two visits not less than 4 weeks apart.

    Tumor burden for a visit was calculated as the sum of the longest diameters of all tumors identified and measured up to that visit. Tumor response at each visit was derived from tumor burden, as follows:

    • Complete response (CR): zero tumor burden
    • Partial response (PR): a 30% or greater decrease in tumor burden
    • Progressive disease (PD): a 20% or greater increase in tumor burden
    • Stable disease (SD): none of the above (a < 30% decrease and < 20% increase in tumor burden)

  2. Number of Participants Alive at the Time of Study Discontinuation or Completion [ Time Frame: At end of study, median duration of treatment was 267 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Previously participated in Study 002/03 and met 1 of the following:

    1. Received the maximum 24 treatment injections in Study 002/03 and had not yet achieved a complete response (CR) and whose response to OncoVEX^GM-CSF indicated that treatment beyond 12 months was warranted, or
    2. Did achieve a CR in Study 002/03 and developed disease progression within 12 months of achieving a CR, or
    3. Terminated treatment in Study 002/03 to allow for treatment of brain metastases. Treatment for brain metastases was no longer ongoing and the patient was able to return to OncoVEX^GM-CSF injections within 3 months of completing treatment for brain metastases.
  2. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.

Exclusion Criteria:

  1. Prior Common Toxicity Criteria for Adverse Events (CTCAE) Grade 3 or 4 toxicity related to OncoVEX^GM-CSF of any organ system (with the exception of injection site reactions, fever and vomiting);
  2. History of Grade 3 fatigue lasting > 1 week while on OncoVEX^GM-CSF treatment;
  3. History of Grade 3 arthralgia/myalgias while on OncoVEX^GM-CSF treatment;
  4. History of ≥ Grade 2 autoimmune reactions, allergic reactions or urticaria or other OncoVEX^GM-CSF-related non-hematological toxicities while on OncoVEX^GM-CSF treatment that required a dose delay or discontinuation of OncoVEX^GM-CSF therapy;
  5. Symptomatic malignant disease progression that required alternative melanoma treatment;
  6. Primary malignancy disease progression despite treatment with OncoVEX^GM-CSF;
  7. Patient requested to be withdrawn from or was unable to comply with the demands of Study 002/03.
  8. Patient was withdrawn from Study 002/03 at the discretion of the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02574260

Sponsors and Collaborators
BioVex Limited
Layout table for investigator information
Study Director: Study Director, MD Amgen
Layout table for additonal information
Responsible Party: BioVex Limited
ClinicalTrials.gov Identifier: NCT02574260    
Other Study ID Numbers: 002/03-E
First Posted: October 12, 2015    Key Record Dates
Results First Posted: December 17, 2015
Last Update Posted: December 17, 2015
Last Verified: November 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Talimogene laherparepvec
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Immunological
Antineoplastic Agents